2013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine

2013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine

2013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer

2013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer

2013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent

2013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent

2013 AACR: Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-110

2013 AACR: Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-110

2012 EORTC: SGI-110 enhances sorafenib activity and alters methylation signature of HCC Cell lines

2012 EORTC: SGI-110 enhances sorafenib activity and alters methylation signature of HCC Cell lines